- Details
- Description
-
Packaging Size100t/bottle
-
Strength40mg
-
CompositonFebuxostat
-
TreatmentChronic Gout,Hyperuricemia (high uric acid in the blood)
-
FormTablet
-
BrandFEBUSODX
-
Quantity Unit40mg*100tablets/Box
-
ManufacturerBIGBEAR Pharma,Laos PDR
About Febuxostat
Febuxostat is used to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. This medicine is a xanthine oxidase inhibitor. It works by causing less uric acid to be produced by the body.
Chronic Gout
Indicated for chronic management of hyperuricemia in patients who:
- Responded inadequately to optimal allopurinol therapy
- Are intolerant to allopurinol
- Treatment with allopurinol not advisable
Initial dose: 40 mg PO qDay
May increase to 80 mg PO qDay after 2 wk if serum uric acid <6 mg/dL is not achieved
Dosage Modifications
Renal impairment
- Mild to moderate (CrCl 30-89 mL/min): No dosage adjustment necessary
- Severe (CrCl <30 mL/min): Not to exceed 40 mg/day
Hepatic impairment
- Mild to moderate (Child-Pugh class A or B): Dosage adjustment not necessary
- Severe (Child-Pugh class C): Data not available; use with caution
Prophylaxis for gout flares during treatment
- Upon initiation, recommend for flare prophylaxis with a nonsteroidal anti-inflammatory drug (NSAID) or colchicine
- Prophylactic therapy may be beneficial for up to 6 months
- If a gout flare occurs, managed gout flare concurrently; treatment does not need to be discontinued
Dosing Considerations
Limitation of use: Not recommended for the treatment of asymptomatic hyperuricemia
Perform serum uric acid level as early as 2 weeks after initiating therapy
